All News

Mobile technology has helped to facilitate communication between pharmacists, patients, and their caregivers.

ViiV Healthcare has submitted a New Drug Application (NDA) for its single-tablet, 2-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.

Study compares 2-year survival between patients with metastatic non-small cell lung cancer treated at academic and community centers.

Certain environmental conditions, such as salinity and temperature, may incite structural changes in myelin sheaths.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Chickenpox parties coordinated through social media are becoming a dangerous trend due to the anti-vaccine movement.

Australia on track to achieve World Health Organization targets for eliminating hepatitis C virus over the next 10 to 15 years.

According to the complaint filed with the consent decree, Keystone's products were not manufactured, processed, packed or held according to CGMP requirements.

The vaccine, produced by Seqirus, was first approved in the United States in August 2016 for adults 18 and older.

To target the infrastructure supporting the illegal online sales of drugs, a series of recent OCI cybercrime investigations focused on credit card processors involved in an arrangement known as “transaction laundering” or “factoring.”

New data from the investigational multiple sclerosis (MS) drug evobrutinib showed that the therapy reduced lesions and decreased annual relapse rates in patients with relapsing MS.

A post hoc analysis of clinical trial data showed oral ozanimod improved cognitive processing speed and reduced annualized relapse rates and MRI lesions in multiple sclerosis.

Anti-tumor necrosis factor (TNF) agents were the most commonly prescribed bDMARDs in this cohort.

The FDA will address new ways to increase the availability of naloxone, during a 2-day advisory committee meeting in December.

Dolutegravir plus lamivudine showed non-inferiority to a 3-drug, first-line regimen in treating HIV infection.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The FDA has approved dupilumab (Dupixent, Regeneron and Sanofi) in patients with moderate-to-severe asthma aged 12 years and older

The first study to evaluate population-level roll-out of pre-exposure prophylaxis (PrEP) for HIV in men who have sex with men has demonstrated rapid decline of new HIV infections.

The switchable CAR T system allows for complete control of the cancer-killing cells, which could improve the treatment’s safety.

The FDA has approved dupilumab (Dupixent, Regeneron and Sanofi) in patients with moderate-to-severe asthma aged 12 years and older.

The FDA has approved dupilumab (Dupixent®, Regeneron and Sanofi) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

Phase 2 data for evobrutinib shows reduction in lesions and relapse rates in patients with multiple sclerosis.

Top news of the day from across the health care landscape.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

An association between hepatitis C virus infection and incident diabetes found among patients who underwent kidney transplantation.

CDC officials note that it is safe to be around infants and young children, pregnant women, or people with weakened immune systems after you get the shingles vaccine.

The updated label changes include information regarding use of rituximab as a follow up treatment in adults with 2 rare forms of vasculitis.

One-time, universal screening of hepatitis C virus (HCV) in the general population is cost-effective and could reduce rates of drug-related HCV cases.